The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial
Open accessAbstract
BACKGROUND: In patients with diabetes, albuminuria is a risk marker of end-stage renal disease and cardiovascular events. An increased renin-angiotensin system activity has been reported to play an important role in the pathological processes in these conditions. We compared the effect of aliskiren, a direct renin inhibitor (DRI), with that of angiotensin receptor blockers (ARBs) on albuminuria and urinary excretion of angiotensinogen, a marker of intrarenal renin-angiotensin system activity. METHODS: We randomly assigned 237 type 2 diabetic patients with high-normal albuminuria (10 to <30 mg/g of albumin-to-creatinine ratio) or microalbuminuria (30 to <300 mg/g) to the DRI group or ARB group (any ARB) with a target blood pressure of <130/80 mmHg. The primary endpoint was a reduction in albuminuria. RESULTS: Twelve patients dropped out during the observation period, and a total of 225 patients were analyzed. During the study period, the systolic and diastolic blood pressures were not different between the groups. The changes in the urinary albumin-to-creatinine ratio from baseline to the end of the treatment period in the DRI and ARB groups were similar (-5.5% and -6.7%, respectively). In contrast, a significant reduction in the urinary excretion of angiotensinogen was observed in the ARB group but not in the DRI group. In the subgroup analysis, a significant reduction in the albuminuria was observed in the ARB group but not in the DRI group among high-normal albuminuria patients. CONCLUSION: DRI and ARB reduced albuminuria in hypertensive patients with type 2 diabetes. In addition, ARB, but not DRI, reduced albuminuria even in patients with normal albuminuria. DRI is not superior to ARB in the reduction of urinary excretion of albumin and angiotensinogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There appears to be inertia to treat residual hypertension in persons with T2D, and pharmacotherapy should be intensified when needed to achieve BP goals.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [249]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Kobori, H., Nangaku, M., Navar, L. G., & Nishiyama, A. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.3.3 · Cited by 1,237
Self-citationUS Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Li, Y., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Ayanian, J., Bragg-Gresham, J., Balkrishnan, R., Chen, J. L. T., Cope, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.014 · Cited by 1,155
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Silveira, M. A. D., Teles, F., Berretta, A., Sanches, T. R., Rodrigues, C. E., Seguro, A. C., & Andrade, L. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1337-7 · Cited by 112
Should ACE inhibitors and ARBs be used in combination in children?
Stotter, B. R., & Ferguson, M. A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4046-8 · Cited by 29
Xian, Y., Dong, L., Jia, Y. R., Lin, Y., Jiao, W., & Wang, Y. (2018) · Cell Biology International · doi:10.1002/cbin.11048 · Cited by 9
Metadata
- Authors
- Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., Takahara, N., Obata, T., Omichi, N., Sakamoto, K., Shingu, R., Taki, H., Nagai, Y., Tokuda, H., Kitada, M., Misawa, M., Nishiyama, A., Kobori, H., Maegawa, H., & The Shiga Committee for Preventing Diabetic Nephropathy
- Affiliations
- Shiga University of Medical Science (JP)
- Kusatsu General Hospital (JP)
- Asahikawa Medical University (JP)
- Kanazawa Medical University (JP)
- Omihachiman Community Medical Center (JP)
- Nagahama City Hospital (JP)
- AKO City Hospital (JP)
- Osaka National Hospital (JP)
- St. Marianna University School of Medicine (JP)
- Nagahama Red Cross Hospital (JP)
- Kagawa University (JP)
- Corresponding author
- Uzu, Takashi
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-12-29
- Volume
- 11
- Issue
- 12
- Pages
- e0164936
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5198982
- OpenAlex
- W2563595666
- Cited by
- 18
- References
- 24
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Japan Diabetes Foundation
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- aliskiren, renin inhibitors, angiotensin receptor blockers, albuminuria, type 2 diabetes, hypertension, angiotensinogen, intrarenal renin-angiotensin system, microalbuminuria, renin-angiotensin system, albumin-creatinine ratio
- MeSH terms
- Renin Inhibitors, Albuminuria, Amides, Angiotensinogen, Antihypertensive Agents, Blood Pressure, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fumarates, Humans, Hypertension, Kidney Failure, Chronic, Prospective Studies, Renin-Angiotensin System, Treatment Outcome, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0164936
- The paper
- Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., Takahara, N., Obata, T., Omichi, N., Sakamoto, K., Shingu, R., Taki, H., Nagai, Y., Tokuda, H., Kitada, M., . . . The Shiga Committee for Preventing Diabetic Nephropathy. (2016). Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0164936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.